Oncology News | pharmaphorum

News

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress.

News

ASCO: Conversational AI tackles missed colonoscopies

An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

ASCO: Conversational AI tackles missed colonoscopies

ASCO: Gilead sifts lung cancer data for efficacy crumbs

ASCO: Novartis’ Scemblix aces first-line CML study

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Gilead’s Trodelvy woes rise with failed bladder cancer trial

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

News

Editor's Picks